Psilocybin Therapy Shows Promise for Treatment-Resistant Depression as Researchers Examine Safety and FDA Approval
Summary
Psilocybin therapy may offer a new treatment for depression that has not improved with conventional antidepressants, following positive Phase 3 trials of Compass Pathways' COMP360 formulation. Research cited also found reduced depression scores versus placebo and suggests benefits alongside supportive psychotherapy may last a year. Experts expect any approved treatment to involve supervised clinical sessions, not prescriptions for home use. Possible risks include anxiety, elevated blood pressure and psychosis in people already at risk, making medical and psychiatric screening important. Trials are difficult to blind because participants can often tell whether they received a psychedelic, leaving questions about how much of the observed benefit is attributable to psilocybin itself. FDA approval remains uncertain.